Summary
Global Markets Direct’s, ‘Yungjin Pharm. Co., Ltd. - Product Pipeline Review - 2016’, provides an overview of the Yungjin Pharm. Co., Ltd.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Yungjin Pharm. Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Yungjin Pharm. Co., Ltd.
- The report provides overview of Yungjin Pharm. Co., Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Yungjin Pharm. Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Yungjin Pharm. Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Yungjin Pharm. Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Yungjin Pharm. Co., Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Yungjin Pharm. Co., Ltd.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Yungjin Pharm. Co., Ltd. Snapshot 5
Yungjin Pharm. Co., Ltd. Overview 5
Key Information 5
Key Facts 5
Yungjin Pharm. Co., Ltd. - Research and Development Overview 6
Key Therapeutic Areas 6
Yungjin Pharm. Co., Ltd. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Yungjin Pharm. Co., Ltd. - Pipeline Products Glance 12
Yungjin Pharm. Co., Ltd. - Late Stage Pipeline Products 12
Pre-Registration Products/Combination Treatment Modalities 12
Phase III Products/Combination Treatment Modalities 13
Yungjin Pharm. Co., Ltd. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Yungjin Pharm. Co., Ltd. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
Yungjin Pharm. Co., Ltd. - Drug Profiles 18
(acetaminophen + tramadol hydrochloride) SR 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
YBH-1603 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
YPL-001 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
YNP-1707 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
YOB-1604 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
ceftaroline fosamil 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
YLS-1501 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
YRA-1909 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
YSA-2021 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
YAC-1912 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
YMS-1716 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
YPC-1811 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
YPP-2022 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
YTD-2020 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Yungjin Pharm. Co., Ltd. - Pipeline Analysis 32
Yungjin Pharm. Co., Ltd. - Pipeline Products by Target 32
Yungjin Pharm. Co., Ltd. - Pipeline Products by Route of Administration 33
Yungjin Pharm. Co., Ltd. - Pipeline Products by Molecule Type 34
Yungjin Pharm. Co., Ltd. - Pipeline Products by Mechanism of Action 35
Yungjin Pharm. Co., Ltd. - Dormant Projects 36
Yungjin Pharm. Co., Ltd. - Locations And Subsidiaries 37
Head Office 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 38
Disclaimer 39
List of Tables
Yungjin Pharm. Co., Ltd., Key Information 5
Yungjin Pharm. Co., Ltd., Key Facts 5
Yungjin Pharm. Co., Ltd. - Pipeline by Indication, 2016 7
Yungjin Pharm. Co., Ltd. - Pipeline by Stage of Development, 2016 9
Yungjin Pharm. Co., Ltd. - Monotherapy Products in Pipeline, 2016 10
Yungjin Pharm. Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016 11
Yungjin Pharm. Co., Ltd. - Pre-Registration, 2016 12
Yungjin Pharm. Co., Ltd. - Phase III, 2016 13
Yungjin Pharm. Co., Ltd. - Phase II, 2016 14
Yungjin Pharm. Co., Ltd. - Phase I, 2016 15
Yungjin Pharm. Co., Ltd. - Preclinical, 2016 16
Yungjin Pharm. Co., Ltd. - Discovery, 2016 17
Yungjin Pharm. Co., Ltd. - Pipeline by Target, 2016 32
Yungjin Pharm. Co., Ltd. - Pipeline by Route of Administration, 2016 33
Yungjin Pharm. Co., Ltd. - Pipeline by Molecule Type, 2016 34
Yungjin Pharm. Co., Ltd. - Pipeline Products by Mechanism of Action, 2016 35
Yungjin Pharm. Co., Ltd. - Dormant Developmental Projects,2016 36
List of Figures
Yungjin Pharm. Co., Ltd. - Pipeline by Top 10 Indication, 2016 7
Yungjin Pharm. Co., Ltd. - Pipeline by Stage of Development, 2016 9
Yungjin Pharm. Co., Ltd. - Monotherapy Products in Pipeline, 2016 10
Yungjin Pharm. Co., Ltd. - Pipeline by Target, 2016 32
Yungjin Pharm. Co., Ltd. - Pipeline by Route of Administration, 2016 33
Yungjin Pharm. Co., Ltd. - Pipeline by Molecule Type, 2016 34
Yungjin Pharm. Co., Ltd. - Pipeline Products by Mechanism of Action, 2016 35
